Drugs / Asunercept
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02853565 | Aug 2016 → Sep 2018 | glioblastoma | CANbridge Life Sciences Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01736436 | Jan 2013 → Dec 2015 | myelodysplastic syndrome | Apogenix GmbH | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03158389 | May 2018 → Feb 2023 | adult glioblastoma | University Hospital Heidelberg | Completed | Mixed |
| Phase 24 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT05447195 | Oct 2021 → Jan 2024 | glioblastoma | CANbridge Life Sciences Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04535674 | Oct 2020 → Oct 2021 | COVID-19, viral pneumonia | Apogenix GmbH | Completed | Missed primary |
| Phase 2 | NCT03746288 | Nov 2018 → Jul 2021 | glioblastoma | CANbridge Life Sciences Ltd. | Unknown | Met primary |
| Phase 2 | NCT01071837 | Dec 2009 → Oct 2014 | glioblastoma | Apogenix GmbH | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04351724 | Apr 2020 → Dec 2021 | COVID-19 | Medical University of Vienna | Unknown | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT05639192 | Nov 2022 → Aug 2023 | COVID-19 | Apogenix GmbH | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2023-03-17 | CANbridge (Suzhou) Bio-pharma Co., Ltd. | Results Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database -Data to be Presented at the ESMO Sarcoma and Rare Cancers Annual Congress -83% overall survival at two years vs. 34.3% OS from institutional database -17.95 months median progression-free survival vs. 5.8 months PFS in historical group canbridgepharma.com ↗
The overall survival rate of the high-dose CAN008 group was 83% at two years and 67% at three, four and five years. |
| 2018-04-12 | CANbridge (Suzhou) Bio-pharma Co., Ltd. | Regulatory CANbridge Receives Approval to Commence CAN008 Phase II/III Trial in Glioblastoma Multiforme (Gbm) in China canbridgepharma.com ↗ |
| 2017-11-02 | CANbridge (Suzhou) Bio-pharma Co., Ltd. | Results CAN008 Injection for the Treatment of Gbm China Taiwan Phase I Data Releasing canbridgepharma.com ↗
Interim safety report showed no SAE happened. |
| 2017-07-26 | CANbridge (Suzhou) Bio-pharma Co., Ltd. | Regulatory CANbridge Congratulates Apogenix APG101 Receiving Ema “Prime” Designation canbridgepharma.com ↗
CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, congratulates Germany’s Apogenix AG, on having received a PRIME designation from the European Medicines Agency (EMA) for APG101 (Asunercept) for the treatment of glioblastoma. |
| 2017-07-18 | CANbridge (Suzhou) Bio-pharma Co., Ltd. | Regulatory CANbridge Submits Ind Application for CAN008 PHII/III Trial in GBM in China canbridgepharma.com ↗
“The IND submission to the CFDA for CANbridge’s first clinical trial in China marks a major milestone for the company,” said James Xue PhD, CANbridge Chairman and CEO. |
| 2016-07-26 | CANbridge (Suzhou) Bio-pharma Co., Ltd. | Regulatory CANbridge’s CAN-008 Approved for Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan canbridgepharma.com ↗ |
| 2016-01-11 | CANbridge (Suzhou) Bio-pharma Co., Ltd. | Results CANbridge Completes Chinese Glioblastoma Biomarker Study for Lead Candidate, CAN008 Plans to Initiate Phase I/II Trial in Taiwan in 2016 canbridgepharma.com ↗
The study demonstrated a high degree of CD95 ligand expression consistency between geographically-diverse Chinese and Western GBM patients. |
All press releases naming this drug 15 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | asunercept | “Asunercept (company code APG101 [Apogenix AG]; company code CAN008 [CANbridge Pharmaceuticals]) is a novel glycosylated fusion protein that has shown promising effectiveness in...” PMID 34911992 ↗ Dec 2021 |
| Known as | APG101 | “an investigational drug (APG101; International Nonproprietary Name: asunercept)” NCT04535674 ↗4“Asunercept (APG101) will be administered once per week as an i.v. infusion” NCT05639192 ↗ |
| Known as | Apocept | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297886 ↗ |
| Known as | Asinercept | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297886 ↗ |
| Known as | CAN008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05447195 ↗ |
| Action | Inhibit | “The target of CAN008 is the inhibition of CD95L.” NCT02853565 ↗ |
| Modality | Protein / enzyme biologic | “APG101 is a fusion protein” NCT01071837 ↗ |
| Route | Intravenous | “100 mg APG101 intravenous weekly” NCT01736436 ↗ |
| Target | FASLG | “Tumor necrosis factor ligand superfamily member 6 binding agent” CHEMBL4297886 ↗ |